AGRX Agile Therapeutics Inc.

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Date	Price Target	Rating	Analyst
11/3/2021	$3.50 → $2.50	Buy	HC Wainwright & Co.
9/13/2021	$7.00 → $3.50	Buy	HC Wainwright & Co.
7/27/2021	$6.00 → $5.00	Outperform	RBC Capital

Agile Therapeutics Inc.

Peers

Recent Analyst Ratings for Agile Therapeutics Inc.

Agile Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Administrative Officer Gilmore Geoffrey returned $30,789 worth of shares to the company (20,256 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Financial Officer Coiante Scott M returned $30,522 worth of shares to the company (20,080 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Supply Chain Officer Conway Robert G returned $20,564 worth of shares to the company (13,529 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Medical Officer Korner Paul returned $20,520 worth of shares to the company (13,500 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Commercial Officer Welsh Amy returned $20,520 worth of shares to the company (13,500 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Director Torrente Josephine returned $1,500 worth of shares to the company (987 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Director Barbari Sharon returned $1,479 worth of shares to the company (973 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Director Carson Sandra returned $1,479 worth of shares to the company (973 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Chief Executive Officer Altomari Alfred returned $72,578 worth of shares to the company (47,749 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Director Fischer Seth H. Z. returned $1,484 worth of shares to the company (976 units at $1.52), closing all direct ownership in the company (SEC Form 4)

Agile Therapeutics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Agile Therapeutics with a new price target

HC Wainwright & Co. reiterated coverage on Agile Therapeutics with a new price target

RBC Capital reiterated coverage on Agile Therapeutics with a new price target

RBC Capital Mkts resumed coverage on Agile Therapeutics with a new price target